January 2011
Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p5
Trade Publication
This article reports on the plan of China Nuokang Bio-Pharmaceutical Inc. to participate in the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, California, in January 2011. The company's management will have a meeting with institutional investors during the conference. China Nuokang is a biopharmaceutical company concentrating on the research, development, manufacture, marketing and sales of medical products.


Related Articles

  • Other News To Note.  // BioWorld Today;5/10/2012, Vol. 23 Issue 91, p3 

    This section offers news briefs from the pharmaceutical biotechnology sector. Joint development activities will be conducted by Aeras and the Infectious Disease Research Institute (IDRI) for ID93/GLA-SE, the tuberculosis vaccine candidate from IDRI. Baizhong Xue, chairman and chief executive...

  • CHINA SFDA ISSUES MANUFACTURING LICENSE TO CHINA NUOKANG.  // Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p1 

    This article reports on a manufacturing license issued by the State Food and Drug Administration (SFDA) of China for the Kaotong product of China Nuokang Bio-Pharmaceutical Inc. According to Baizhong Xue, chairman and chief executive officer (CEO) at the biotechnology company, they are...

  • Other News To Note.  // BioWorld Today;1/12/2012, Vol. 23 Issue 8, p3 

    This section offers news briefs on the biopharmaceutical industry. Burrill and Co. completed the first close of its Burrill Brazil Fund I. Bridge Bioresearch PLC completed preclinical trials of 2-hydroxyoleic acid for obesity and metabolic disorders. China Nuokang Bio-Pharmaceutical Inc....

  • Biotech Execs in Chilly NYC with Warm Outlook. Harris, Michael J. // BioWorld Today;2/14/2011, Vol. 22 Issue 30, p1 

    The article discusses the highlights of the 13th annual Biotechnology International Organization (BIO) CEO & Investor Conference held in New York City from February 14-15, 2011. Attendees discussed the financial and investment landscape issues affecting continued post-recession growth in the...

  • WALL ST./FINANCE.  // MondayMorning;1/25/2010, Vol. 18 Issue 3, p3 

    The article offers news briefs related to corporate finance in the health care industry in the U.S. and China. Team Health Holdings LLC has closed at 14.90 dollars, up 2.90 dollars from its initial public offering (IPO) price of 12.00 dollars. Concord Medical Services Holdings Ltd. has closed at...

  • Panel: Dark Age Ahead for European Biotechs. Brosky, John // BioWorld Today;11/19/2008, Vol. 19 Issue 226, p1 

    The article discusses the highlights of the sixth annual gathering of experts for the session "A Day in the Life of Experienced Dealmakers" during the BIOEurope 2008 conference in Mannheim, Germany. According to the panel of investors and pharmaceutical executives, small biotechnology...

  • Panel: Focus on Long Term to Weather Economic Storm. Boggs, Jennifer // BioWorld Today;11/3/2008, Vol. 19 Issue 214, p1 

    The article discusses the highlights of 2008 Biotechnology Industry Organization's annual investor forum. Topics addressed at the forum include factors that have had an impact on the U.S. industry like consumer spending, housing and multiple interest rates, and the need to focus on the...

  • Strategic vs. Financial Backers: Balance Tricky but Worthwhile. Osborne, Randy // BioWorld Today;5/20/2009, Vol. 20 Issue 96, p1 

    The article highlights a panel discussion about strategic investors and financial backers for biotechnology firms presented at the Biotechnology Industry Organization (BIO) International Convention in Atlanta, Georgia on May 19, 2009. Key figures indicate that companies with strategic investors...

  • Biotech Comp angers Investors. Santini, Laura // Investment Dealers' Digest;3/3/2003, Vol. 69 Issue 9, p11 

    Focuses on the financial conditions of investors who invested in biotechnology companies in the U.S. Lack of profit increments for investors; Decrease in share prices of biotechnology companies; Increase in salary levels of the biotechnology executives; Frustration of investors over increase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics